AAV Frataxin Vector Using PGK-WPRE Expression Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current AAV vectors used in gene therapy for Friedreich's ataxia either over- or under-express frataxin and fail to reach all target cells and neurons affected by the disease, making them unsuitable for effective treatment.
Innovation Solution
An AAV vector comprising a nucleic acid sequence encoding frataxin, a phosphoglycerate-kinase (PGK) promoter, and a woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) is developed to enhance and regulate frataxin expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If current AAV vectors are used to express frataxin, then frataxin expression is achieved, but the expression levels are either too high or too low and do not reach all target cells effectively
Solution Approach 1:
The patent modifies the promoter sequence (using phosphoglycerate-kinase promoter), adds post-transcriptional regulatory elements (WPRE), and optimizes the coding sequence to achieve optimal frataxin expression levels that are neither too high nor too low, thereby resolving the contradiction between expression quantity and treatment effectiveness
Solution Approach 2:
The patent introduces intermediary elements between the promoter and the coding sequence, including the WPRE (woodchuck hepatitis virus posttranscriptional regulatory element) and optimized linkers, which act as mediators to regulate and optimize frataxin expression levels for effective treatment
Data Source
AI summary
The present invention provides gene therapies for the treatment of Friedreich's ataxia. Specifically, the present invention provides a nucleic acid, cloning vector and transfer vector for the production of an adeno-associated virus (AAV) vector. The nucleic acid comprises (i) a nucleic acid sequence encoding frataxin, (ii) a phospho-glycerate-kinase (PGK) promoter, and (iii) a woodchuck hepatitis virus posttranscriptional regulatory element (WPRE). The present invention also provides a pharmaceutical composition which comprises the AAV vector or nucleic acid. Also, the AAV vector, nucleic acid or pharmaceutical composition can be used as a medicament, specifically as a medicament for the treatment of Friedreich's ataxia.